Patient P-01781
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
83%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 51 SC-12 recommended — Supportive Compound SC-12
- Day 52 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 51.
Primary contributors, last 14 days
- GI instability-9
- Nutritional resilience+7
- Toxicity+7
- Treatment adherence+3
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −26%
- Supportive Compound SC-12Day 51Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
85%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 52 and rising
- WearableSleep 5.2 h, below personal baseline
- Autonomic recovery ↑40
- Wearable3,719 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 45 ms
- Sleep
- 5.4 h
- Steps
- 3,327
- Resting HR
- 68 bpm
Daily log: GI score 52, nutritional resilience 46, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01436 | 60% | S14 | GI-04 | improved | 38 |
| P-01556 | 60% | S14 | GI-04 | improved | 44 |
| P-01389 | 54% | S14 | SC-12 | improved | 46 |
| P-01544 | 54% | S15 | GI-04 | improved | 50 |
| P-01570 | 54% | S14 | SC-12 | improved | 46 |
| P-01356 | 53% | S14 | GI-04 | improved | 42 |
| P-01365 | 52% | S14 | SC-12 | improved | 49 |
| P-01505 | 52% | S14 | NP-02 | improved | 41 |
| P-01307 | 51% | S14 | GI-04 | improved | 43 |
| P-01433 | 51% | S14 | GI-04 | improved | 48 |
| P-01438 | 51% | S14 | GI-04 | improved | 56 |
| P-01494 | 51% | S14 | GI-04 | improved | 42 |